Moreover, in TCGA-BLCA and GEO cohorts, patients with high PDE4B expression experienced aggressive clinicopathological characteristics and unfavorable prognosis, compared with those low PDE4B expression. The gene discussed is PDE4B; the disease is bladder transitional cell carcinoma.